+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Future of Venous Leg Ulcers (Crural ulcer) R&D Pipeline Drugs and Companies- Analysis of Global Venous Leg Ulcers (Crural ulcer) Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

  • ID: 4745219
  • Report
  • January 2019
  • Region: Global
  • 60 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Aurealis Pharma AG
  • CytoTools AG
  • Daval International Ltd
  • Factor Therapeutics Ltd
  • FirstString Research Inc
  • Hypo-Stream Ltd
  • MORE
The global demand for Venous Leg Ulcers (Crural ulcer) treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Venous Leg Ulcers (Crural ulcer) pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Venous Leg Ulcers (Crural ulcer) pipeline companies from advancing their products into Phase 3 or Phase 4.

Venous Leg Ulcers (Crural ulcer) Report Description

The H1- 2019 pipeline review report on Venous Leg Ulcers (Crural ulcer) pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Venous Leg Ulcers (Crural ulcer) pipeline compounds.

The Venous Leg Ulcers (Crural ulcer) pipeline guide presents information on all active drugs currently being developed for Venous Leg Ulcers (Crural ulcer). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Venous Leg Ulcers (Crural ulcer) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Venous Leg Ulcers (Crural ulcer) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Venous Leg Ulcers (Crural ulcer) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Venous Leg Ulcers (Crural ulcer) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Venous Leg Ulcers (Crural ulcer) pipeline report includes
  • An overview of Venous Leg Ulcers (Crural ulcer) disease including symptoms, causes, diagnosis and available treatment options is provided.
  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
  • Phase wise count of pipeline compounds
  • Company wise list of pipeline compounds
  • Mechanism of Action wise pipeline compounds
For each pipeline product, the following details are provided
  • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
  • Current status of development
  • Drug overview
  • Mechanism of Action
  • Pre-clinical and Clinical Trials
Reasons to Buy
  • The report is designed to help industry executives promote the success and continued growth of their organizations
  • Get clear understanding of the entire Venous Leg Ulcers (Crural ulcer) pipeline, with details on active projects
  • Stay ahead of the competition through comprehensive knowledge of Venous Leg Ulcers (Crural ulcer) pipeline progress
  • Get in detail information of each product with updated information on each project along with key milestones
  • Gain clear insights into the market through in-depth strategic analysis review
  • Know the list of companies participating in global Venous Leg Ulcers (Crural ulcer) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
The report will be delivered in 2 working days.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aurealis Pharma AG
  • CytoTools AG
  • Daval International Ltd
  • Factor Therapeutics Ltd
  • FirstString Research Inc
  • Hypo-Stream Ltd
  • MORE
1.1 List of Tables
1.2 List of Figures

2. Global Venous Leg Ulcers (Crural ulcer) Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology

3. Executive Summary
3.1 Venous Leg Ulcers (Crural ulcer) Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Venous Leg Ulcers (Crural ulcer) pipeline, H1- 2019
3.5 Mechanism of Action wise Venous Leg Ulcers (Crural ulcer) Pipeline Candidates

4. Aurealis Pharma AG Venous Leg Ulcers (Crural ulcer) Pipeline Details
4.1 Aurealis Pharma AG Business Profile
4.2 Aurealis Pharma AG Venous Leg Ulcers (Crural ulcer) Drug Details
4.2.1 Drug Snapshot
4.2.1.1 Originator
4.2.1.2 Collaborator/Co-Developer
4.2.1.3 Route of Administration
4.2.1.4 Orphan Drug/Fast Track/Special Designation
4.2.1.5 Area
4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5. CardioVascular BioTherapeutics Inc Venous Leg Ulcers (Crural ulcer) Pipeline Details
5.1 CardioVascular BioTherapeutics Inc Business Profile
5.2 CardioVascular BioTherapeutics Inc Venous Leg Ulcers (Crural ulcer) Drug Details
5.2.1 Drug Snapshot
5.2.1.1 Originator
5.2.1.2 Collaborator/Co-Developer
5.2.1.3 Route of Administration
5.2.1.4 Orphan Drug/Fast Track/Special Designation
5.2.1.5 Area
5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6. CytoTools AG Venous Leg Ulcers (Crural ulcer) Pipeline Details
6.1 CytoTools AG Business Profile
6.2 CytoTools AG Venous Leg Ulcers (Crural ulcer) Drug Details
6.2.1 Drug Snapshot
6.2.1.1 Originator
6.2.1.2 Collaborator/Co-Developer
6.2.1.3 Route of Administration
6.2.1.4 Orphan Drug/Fast Track/Special Designation
6.2.1.5 Area
6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7. Daval International Ltd Venous Leg Ulcers (Crural ulcer) Pipeline Details
7.1 Daval International Ltd Business Profile
7.2 Daval International Ltd Venous Leg Ulcers (Crural ulcer) Drug Details
7.2.1 Drug Snapshot
7.2.1.1 Originator
7.2.1.2 Collaborator/Co-Developer
7.2.1.3 Route of Administration
7.2.1.4 Orphan Drug/Fast Track/Special Designation
7.2.1.5 Area
7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8. Factor Therapeutics Ltd Venous Leg Ulcers (Crural ulcer) Pipeline Details
8.1 Factor Therapeutics Ltd Business Profile
8.2 Factor Therapeutics Ltd Venous Leg Ulcers (Crural ulcer) Drug Details
8.2.1 Drug Snapshot
8.2.1.1 Originator
8.2.1.2 Collaborator/Co-Developer
8.2.1.3 Route of Administration
8.2.1.4 Orphan Drug/Fast Track/Special Designation
8.2.1.5 Area
8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9. FirstString Research Inc Venous Leg Ulcers (Crural ulcer) Pipeline Details
9.1 FirstString Research Inc Business Profile
9.2 FirstString Research Inc Venous Leg Ulcers (Crural ulcer) Drug Details
9.2.1 Drug Snapshot
9.2.1.1 Originator
9.2.1.2 Collaborator/Co-Developer
9.2.1.3 Route of Administration
9.2.1.4 Orphan Drug/Fast Track/Special Designation
9.2.1.5 Area
9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10. Hypo-Stream Ltd Venous Leg Ulcers (Crural ulcer) Pipeline Details
10.1 Hypo-Stream Ltd Business Profile
10.2 Hypo-Stream Ltd Venous Leg Ulcers (Crural ulcer) Drug Details
10.2.1 Drug Snapshot
10.2.1.1 Originator
10.2.1.2 Collaborator/Co-Developer
10.2.1.3 Route of Administration
10.2.1.4 Orphan Drug/Fast Track/Special Designation
10.2.1.5 Area
10.2.1.6 Type of Molecular Entity
10.3 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11. Ilkos Therapeutics Inc Venous Leg Ulcers (Crural ulcer) Pipeline Details
11.1 Ilkos Therapeutics Inc Business Profile
11.2 Ilkos Therapeutics Inc Venous Leg Ulcers (Crural ulcer) Drug Details
11.2.1 Drug Snapshot
11.2.1.1 Originator
11.2.1.2 Collaborator/Co-Developer
11.2.1.3 Route of Administration
11.2.1.4 Orphan Drug/Fast Track/Special Designation
11.2.1.5 Area
11.2.1.6 Type of Molecular Entity
11.3 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments

12. MallInckrodt Plc Venous Leg Ulcers (Crural ulcer) Pipeline Details
12.1 MallInckrodt Plc Business Profile
12.2 MallInckrodt Plc Venous Leg Ulcers (Crural ulcer) Drug Details
12.2.1 Drug Snapshot
12.2.1.1 Originator
12.2.1.2 Collaborator/Co-Developer
12.2.1.3 Route of Administration
12.2.1.4 Orphan Drug/Fast Track/Special Designation
12.2.1.5 Area
12.2.1.6 Type of Molecular Entity
12.3 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments

13. MediWound Ltd Venous Leg Ulcers (Crural ulcer) Pipeline Details
13.1 MediWound Ltd Business Profile
13.2 MediWound Ltd Venous Leg Ulcers (Crural ulcer) Drug Details
13.2.1 Drug Snapshot
13.2.1.1 Originator
13.2.1.2 Collaborator/Co-Developer
13.2.1.3 Route of Administration
13.2.1.4 Orphan Drug/Fast Track/Special Designation
13.2.1.5 Area
13.2.1.6 Type of Molecular Entity
13.3 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments

14. Promore Pharma AB Venous Leg Ulcers (Crural ulcer) Pipeline Details
14.1 Promore Pharma AB Business Profile
14.2 Promore Pharma AB Venous Leg Ulcers (Crural ulcer) Drug Details
14.2.1 Drug Snapshot
14.2.1.1 Originator
14.2.1.2 Collaborator/Co-Developer
14.2.1.3 Route of Administration
14.2.1.4 Orphan Drug/Fast Track/Special Designation
14.2.1.5 Area
14.2.1.6 Type of Molecular Entity
14.3 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments

15. Latest Venous Leg Ulcers (Crural ulcer) Drug Pipeline Developments, 2019

16. Appendix
16.1 About Us
16.2 Sources and Methodology
16.3 Contact Information
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aurealis Pharma AG
  • CardioVascular BioTherapeutics Inc
  • CytoTools AG
  • Daval International Ltd
  • Factor Therapeutics Ltd
  • FirstString Research Inc
  • Hypo-Stream Ltd
  • Ilkos Therapeutics Inc
  • MallInckrodt Plc
  • MediWound Ltd
  • Promore Pharma AB
Note: Product cover images may vary from those shown
Adroll
adroll